|
1. 行政院衛生民國96年主要死因統計. 2. Parkin, D.M., The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 2008(218): p. 12-20. 3. Jemal, A., et al., Cancer statistics, 2008. CA Cancer J Clin, 2008. 58(2): p. 71-96. 4. Murta-Nascimento, C., et al., Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol, 2007. 25(3): p. 285-95. 5. Lower, G.M., Jr., Concepts in causality: chemically induced human urinary bladder cancer. Cancer, 1982. 49(5): p. 1056-66. 6. 陶聲洋防癌基金會. 7. Spiess, P.E. and B. Czerniak, Dual-track pathway of bladder carcinogenesis: practical implications. Archives of Pathology & Laboratory Medicine, 2006. 130(6): p. 844-852. 8. Barocas, D.A. and P.E. Clark, Bladder cancer. Curr Opin Oncol, 2008. 20(3): p. 307-14. 9. Gee, J., A.L. Sabichi, and H.B. Grossman, Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol, 2002. 43(3): p. 277-86. 10. Amling, C.L., Diagnosis and management of superficial bladder cancer. Curr Prob Cancer, 2001. 25(4): p. 219-278. 11. Margolis, R.L. and L. Wilson, Microtubule treadmilling: what goes around comes around. Bioessays, 1998. 20(10): p. 830-6. 12. Chang, P. and T. Stearns, Delta-tubulin and epsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function. Nat Cell Biol, 2000. 2(1): p. 30-5. 13. Nigg, E.A., Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol, 2001. 2(1): p. 21-32. 14. Zheng, Y., M.K. Jung, and B.R. Oakley, Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell, 1991. 65(5): p. 817-23. 15. Amos, L.A., Focusing-in on microtubules. Curr Opin Struct Biol, 2000. 10(2): p. 236-41. 16. Dowling, M., et al., Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol Ther, 2005. 4(2): p. 197-206. 17. Wang, L.G., et al., The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemoth Pharm, 1999. 44(5): p. 355-61. 18. McKiernan, J.M., et al., Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol, 2006. 24(19): p. 3075-3080. 19. Saloustros, E., D. Mavroudis, and V. Georgoulias, Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother, 2008. 9(15): p. 2603-16. 20. Jordan, A., et al., Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev, 1998. 18(4): p. 259-96. 21. Hamel, E. and C.M. Lin, Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol, 1983. 32(24): p. 3864-7. 22. Wall, M.E., et al., Plant antitumor agents. 3. A convenient separation of tannins from other plant constituents. J Pharm Sci, 1969. 58(7): p. 839-41. 23. Lin, C.M., et al., Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol, 1988. 34(2): p. 200-8. 24. Vincent, L., et al., Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest, 2005. 115(11): p. 2992-3006. 25. Griggs, J., J.C. Metcalfe, and R. Hesketh, Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol, 2001. 2(2): p. 82-7. 26. Quan, H., Y. Xu, and L. Lou, p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer, 2008. 122(8): p. 1730-7. 27. Tozer, G.M., et al., Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res, 1999. 59(7): p. 1626-1634. 28. Kanthou, C., et al., The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am J Pathol, 2004. 165(4): p. 1401-1411. 29. Stevenson, J.P., et al., Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol, 2003. 21(23): p. 4428-4438. 30. Nabha, S.M., et al., Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res, 2002. 8(8): p. 2735-41. 31. de Bruin, E.C. and J.P. Medema, Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev, 2008. 34(8): p. 737-49. 32. Vitale, I., et al., Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis, 2007. 12(1): p. 155-166. 33. Lin, H.L., et al., Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther, 2007. 323(1): p. 365-73. 34. Petit, I., et al., The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood, 2008. 111(4): p. 1951-61. 35. Dumontet, C. and B.I. Sikic, Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol, 1999. 17(3): p. 1061-70. 36. Deng, L., et al., MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res, 2002. 112: p. 49-66. 37. Kuo, C.C., et al., BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res, 2004. 64(13): p. 4621-4628. 38. Chin, Y.R. and A. Toker, Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal, 2009. 21(4): p. 470-6. 39. Sheng, S., M. Qiao, and A.B. Pardee, Metastasis and AKT activation. J Cell Physiol, 2009. 218(3): p. 451-4. 40. Simoni, D., et al., Novel combretastatin analogues endowed with antitumor activity. J Med Chem, 2006. 49(11): p. 3143-52. 41. Bernhard, E.J., et al., Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. Int J Radiat Biol, 1996. 69(5): p. 575-84. 42. Yoshida, M., et al., Biochemical differences between staurosporine-induced apoptosis and premature mitosis. Exp Cell Res, 1997. 232(2): p. 225-39. 43. Vakifahmetoglu, H., M. Olsson, and B. Zhivotovsky, Death through a tragedy: mitotic catastrophe. Cell Death Differ, 2008. 15(7): p. 1153-62. 44. Chade, D.C., et al., Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J Exp Clin Cancer Res, 2008. 27: p. 78. 45. Pettit, G.R., et al., Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Design, 1995. 10(4): p. 299-309.
|